FDG PET/CT for Primary Staging of Lung Cancer and Mesothelioma

Thai, 2021, Lung cancer, Lancet, 398, 535, 10.1016/S0140-6736(21)00312-3 Lim, 2018, The 8(th) lung cancer TNM classification and clinical staging system: review of the changes and clinical implications, Quant Imaging Med Surg, 8, 709, 10.21037/qims.2018.08.02 Kandathil, 2018, Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non-Small Cell Lung Cancer, Radiographics, 38, 2134, 10.1148/rg.2018180060 Ettinger, 2021, NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021, J Natl Compr Canc Netw, 19, 254, 10.6004/jnccn.2021.0013 Postmus, 2017, Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 28, iv1, 10.1093/annonc/mdx222 2019, ACR Appropriateness Criteria((R)) Noninvasive Clinical Staging of Primary Lung Cancer, J Am Coll Radiol, 16, S184 van Tinteren, 2002, Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial, Lancet, 359, 1388, 10.1016/S0140-6736(02)08352-6 Zukotynski, 2022, Clinical Applications of Artificial Intelligence in Positron Emission Tomography of Lung Cancer, PET Clin, 17, 77, 10.1016/j.cpet.2021.09.001 Weir-McCall, 2021, Impact of solitary pulmonary nodule size on qualitative and quantitative assessment using 18F-fluorodeoxyglucose PET/CT: the SPUTNIK trial, Eur J Nucl Med Mol Imaging, 48, 1560, 10.1007/s00259-020-05089-y Kim, 2014, Pulmonary subsolid nodules: what radiologists need to know about the imaging features and management strategy, Diagn Interv Radiol, 20, 47 Feng, 2019, The new 8th TNM staging system of lung cancer and its potential imaging interpretation pitfalls and limitations with CT image demonstrations, Diagn Interv Radiol, 25, 270, 10.5152/dir.2019.18458 Travis, 2016, The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer, J Thorac Oncol, 11, 1204, 10.1016/j.jtho.2016.03.025 Vaz, 2022, Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2- [(18)F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0, Eur J Nucl Med Mol Imaging, 49, 1386, 10.1007/s00259-021-05624-5 Wu, 2013, Diagnostic value of fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for the detection of metastases in non-small-cell lung cancer patients, Int J Cancer, 132, E37, 10.1002/ijc.27779 Schaffler, 2004, Non-small cell lung cancer: evaluation of pleural abnormalities on CT scans with 18F FDG PET, Radiology, 231, 858, 10.1148/radiol.2313030785 Li, 2021, Predicting the nature of pleural effusion in patients with lung adenocarcinoma based on (18)F-FDG PET/CT, EJNMMI Res, 11, 108, 10.1186/s13550-021-00850-2 Xu, 2020, Imaging features and prognostic value of (18)F-FDG PET/CT detection of soft-tissue metastasis from lung cancer: a retrospective study, BMC Cancer, 20, 596, 10.1186/s12885-020-07080-0 Kruger, 2009, Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT, Eur J Nucl Med Mol Imaging, 36, 1807, 10.1007/s00259-009-1181-2 Dibble, 2019, Utility of FDG-PET/CT in Patients with Advanced Renal Cell Carcinoma with Osseous Metastases: Comparison with CT and Tc-99(m)-MDP Bone Scan in a Prospective Clinical Trial, Kidney Cancer, 3, 241, 10.3233/KCA-190075 Taira, 2007, Detection of bone metastases: assessment of integrated FDG PET/CT imaging, Radiology, 243, 204, 10.1148/radiol.2431052104 Wu, 2017, The utility of 18F-FDG PET/CT for the diagnosis of adrenal metastasis in lung cancer: a PRISMA-compliant meta-analysis, Nucl Med Commun, 38, 1117, 10.1097/MNM.0000000000000757 2021, ACR Appropriateness Criteria(R) Adrenal Mass Evaluation: 2021 Update, J Am Coll Radiol, 18, S251 Akkus, 2019, Diagnostic efficacy of 18F-FDG PET/CT in patients with adrenal incidentaloma, Endocr Connect, 8, 838, 10.1530/EC-19-0204 Tan, 2014, FDG PET/CT in the liver: lesions mimicking malignancies, Abdom Imaging, 39, 187, 10.1007/s00261-013-0043-3 Martucci, 2019, Impact of (18)F-FDG PET/CT in Staging Patients With Small Cell Lung Cancer: A Systematic Review and Meta-Analysis, Front Med (Lausanne), 6, 336, 10.3389/fmed.2019.00336 Asciak, 2021, Update on biology and management of mesothelioma, Eur Respir Rev, 30, 200226, 10.1183/16000617.0226-2020 Elliott, 2018, (18)F-FDG PET/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center, Br J Radiol, 91 Wilcox, 2009, Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma, Clin Lung Cancer, 10, 244, 10.3816/CLC.2009.n.033 Erasmus, 2005, Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications, J Thorac Cardiovasc Surg, 129, 1364, 10.1016/j.jtcvs.2004.10.034 Ettinger, 2016, NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016, J Natl Compr Canc Netw, 14, 825, 10.6004/jnccn.2016.0087 Kitajima, 2016, Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma, Jpn J Radiol, 34, 537, 10.1007/s11604-016-0555-1 Lopci, 2021, PET/CT Variants and Pitfalls in Lung Cancer and Mesothelioma, Semin Nucl Med, 51, 458, 10.1053/j.semnuclmed.2021.04.002 Berzenji, 2018, The eighth TNM classification for malignant pleural mesothelioma, Transl Lung Cancer Res, 7, 543, 10.21037/tlcr.2018.07.05